Harvard Medical School

SIP Brain Health Innovation Olympics Awards Global Student Teams in Intergenerational Competition

Retrieved on: 
Wednesday, April 3, 2024
University, Harvard Medical School, Season, Innovation, Rotman School of Management, Entrepreneurship, Massachusetts General Hospital, Science, Dartmouth College, Sodexo, Senior, Student, Asian Institute of Management, Olympic Games, Hospital, SIP, Management

Participating students from colleges and universities around the world joined SIP's Brain Health Innovation Olympics challenge to create Brain Health Centers of Excellence.

Key Points: 
  • Participating students from colleges and universities around the world joined SIP's Brain Health Innovation Olympics challenge to create Brain Health Centers of Excellence.
  • Winning concepts include fully integrated solutions to deliver Brain Health Centers of Excellence in Senior Living Communities, Brain Health incubators and investment funds, workplace brain health programs, and increased caregiver support.
  • The 2nd Season of the Brain Health Innovation Olympics represents a significant step forward in advancing brain health initiatives globally.
  • For more information about Social Impact Partners and the Brain Health Innovation Olympics, please visit www.socialimpact.partners and join SIP's Global Brain Health and Longevity Initiative.

New Research From Inovalon and Harvard Analyzes Medicare Advantage Plan Design Impact on Healthcare Utilization and Health Equity

Retrieved on: 
Monday, April 8, 2024
Harvard Medical School, HMO, Health, Preferred provider organization, Importance, Inovalon, Research, Health maintenance organization, PPO, Medicare, Medicare Advantage, FFS, Health insurance

The findings, published in the white paper " The Importance of Plan Design in Medicare Advantage ," represent the fourth installment of Inovalon’s and Harvard Medical School’s research collaboration to understand the underlying factors influencing enrollment, quality outcomes, and utilization in MA vs. FFS Medicare.

Key Points: 
  • The findings, published in the white paper " The Importance of Plan Design in Medicare Advantage ," represent the fourth installment of Inovalon’s and Harvard Medical School’s research collaboration to understand the underlying factors influencing enrollment, quality outcomes, and utilization in MA vs. FFS Medicare.
  • Previous research found that MA delivers superior quality outcomes and utilization reductions compared to FFS Medicare, even after controlling for differences in who enrolls.
  • However, until now, there was limited data on the differences within MA, and how specific MA plan designs and features impact outcomes.
  • "By understanding the populations Medicare Advantage plans attract, policymakers and health plans can come together to incentivize and deliver superior, cost-effective outcomes for every Medicare enrollee."

NeuroVigil, World’s Most Valuable Neurotech, Launches iBrain™ in US

Retrieved on: 
Friday, April 5, 2024
Head, Roche, MIT Technology Review, IP, FCCP, Clinic, Seed, Consciousness, Partnership, Novartis, SAN, DNA, Aneurysm, Critical care, Stanford School, Cedars-Sinai Medical Center, Lawyer, Harvard Medical School, DSS, University, MD, Hospital, FDA, Apnea, Brain, ALS, MIT, Neocortex, Biomarker, Bird, Doctor of Philosophy, Human, Brain tumor, BCIS, Silicon, Patent, VCS, Division

The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.

Key Points: 
  • The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.
  • A joint abstract by Dr. Low and Dr. Hawking featuring Dr. Hawking’s brain patterns analyzed by NeuroVigil’s technology was released as early as 2012.
  • The technology was also successfully demonstrated on ALS sufferer Augie Nieto in 2013 who spelled “COMMUNICATE” with his mind.
  • In the past two years, NeuroVigil has recruited talent from Amgen, Roche, Novartis and MIT in preparation for the launch.

CORRECTION -- NeuroVigil, World’s Most Valuable Neurotech Company, Launches in US

Retrieved on: 
Friday, April 5, 2024
Head, Roche, MIT Technology Review, IP, FCCP, Clinic, Seed, Consciousness, Partnership, Novartis, SAN, DNA, Aneurysm, Critical care, Stanford School, Cedars-Sinai Medical Center, Lawyer, Harvard Medical School, DSS, University, MD, Hospital, FDA, Apnea, Brain, ALS, MIT, Neocortex, Biomarker, Bird, Doctor of Philosophy, Human, Brain tumor, BCIS, Patent, VCS, Division

“Who needs implants when you have the real deal?” said Dr. Philip Low, PhD, NeuroVigil’s Chairman, Chief Executive and Technology Officer, Founder and Supermajority Owner.

Key Points: 
  • “Who needs implants when you have the real deal?” said Dr. Philip Low, PhD, NeuroVigil’s Chairman, Chief Executive and Technology Officer, Founder and Supermajority Owner.
  • The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.
  • The technology was also successfully demonstrated on ALS sufferer Augie Nieto in 2013 who spelled “COMMUNICATE” with his mind.
  • In the past two years, NeuroVigil has recruited talent from Amgen, Roche, Novartis and MIT in preparation for the launch.

NeuroVigil, World’s Most Valuable Neurotech Company, Launches in US

Retrieved on: 
Friday, April 5, 2024
Head, Roche, MIT Technology Review, IP, FCCP, Clinic, Seed, Consciousness, Partnership, Novartis, SAN, DNA, Aneurysm, Critical care, Stanford School, Cedars-Sinai Medical Center, Lawyer, Harvard Medical School, DSS, University, MD, Hospital, FDA, Apnea, Brain, ALS, MIT, Neocortex, Biomarker, Bird, Doctor of Philosophy, Human, Brain tumor, BCIS, Silicon, Patent, VCS, Division

The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.

Key Points: 
  • The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.
  • A joint abstract by Dr. Low and Dr. Hawking featuring Dr. Hawking’s brain patterns analyzed by NeuroVigil’s technology was released as early as 2012.
  • The technology was also successfully demonstrated on ALS sufferer Augie Nieto in 2013 who spelled “COMMUNICATE” with his mind.
  • In the past two years, NeuroVigil has recruited talent from Amgen, Roche, Novartis and MIT in preparation for the launch.

TearSolutions, Inc. Appoints Louis M Alpern, MD, MPH, FACS, FICS to its Board of Directors

Retrieved on: 
Wednesday, April 3, 2024
Principal, Harvard Medical School, Alpern, Public, Public health, FICS, Private practice, Telecanthus, Patient, DED, MPH, Therapy, FACS, Frustration, Ophthalmology, Pharmaceutical industry

“Dr.

Key Points: 
  • “Dr.
  • Alpern brings extensive real-world clinical experience treating patients with ocular surface disease, having prescribed or trialed virtually every dry eye treatment available,” said Anil Asrani, President and CEO of TearSolutions.
  • “Dr.
  • He received his Doctor of Medicine from Harvard Medical School and his Master of Public Health from the Harvard School of Public Health.

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

Retrieved on: 
Wednesday, April 3, 2024
Harvard Medical School, Dana–Farber Cancer Institute, GBM, Code, Glioblastoma, Clinical trial, Society, Brigham and Women's Hospital, Hospital, Tokyo Stock Exchange, ASCO, Neuro-Oncology (journal), Annual general meeting

LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) has been selected for an oral presentation at the American Society of Clinical Oncology (2024 ASCO) Annual Meeting to be held May 31 – June 4, 2024 in Chicago.

Key Points: 
  • LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) has been selected for an oral presentation at the American Society of Clinical Oncology (2024 ASCO) Annual Meeting to be held May 31 – June 4, 2024 in Chicago.
  • The oral presentation will be presented by one of the investigators of this clinical trial, Gilbert Youssef, M.D., Attending Physician at Harvard Medical School, Center for Neuro-Oncology at Dana-Farber Cancer Institute and Brigham and Women's Hospital.
  • The presentation details are as follows:

Autolus Therapeutics Announces Changes to its Board of Directors

Retrieved on: 
Monday, April 1, 2024
Cubist Pharmaceuticals, DBV Technologies, MB, Alnylam Pharmaceuticals, Harvard Medical School, University of Cambridge, Faculty, Imperial College London, Development, GSK plc, Biologics license application, Hematology, Patient, ALL, Merck, Bristol Myers Squibb, Marketing, Biogen, Doctor of Philosophy, Bates College, Oxford Biomedica, Sarepta Therapeutics, Pharmaceutical medicine, Therapy, Swedish Orphan Biovitrum, Royal college, FDA, BLA, Autoimmunity, Economics, Food, Pharmaceutical industry

John H. Johnson advised the Board of his decision to step down from his role as Chairman of the Board and Non-Executive Director.

Key Points: 
  • John H. Johnson advised the Board of his decision to step down from his role as Chairman of the Board and Non-Executive Director.
  • We wish John much success with his new projects,” said Dr. Christian Itin, Chief Executive Officer of Autolus.
  • He is currently a director of Alnylam Pharmaceuticals and chair of Dunad Therapeutics and Gulf of Maine Research Institute.
  • Mr. Bonney has served as a director with many companies previously including Celgene, Kaleido Biosciences, Magenta Therapeutics, Bristol Myers Squibb, Sarepta Therapeutics and Syros Pharmaceuticals.

Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs

Retrieved on: 
Monday, April 1, 2024
Harvard Medical School, Investigational device exemption, Human, Obesity, Cardiovascular disease, Exercise, Risk, Patient, Food and Drug Administration, Weight loss, IDE, MD, Diet, Pharmacotherapy, Duodenum, Hospital, T2D, Wellness, Pathology, Therapy, BMI, FDA, Endoscopy, Food, Pharmaceutical industry

BURLINGTON, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced U.S. Food and Drug Administration (FDA) approval of a pivotal Investigational Device Exemption (IDE) to study Revita’s efficacy in maintaining weight loss following the discontinuation of GLP-1 receptor agonist (GLP-1RA) drug therapy, addressing a key unmet need in the treatment of obesity. Obesity affects over 40% of the US population and is a critical precursor to various highly morbid and expensive chronic conditions such as type 2 diabetes, metabolic dysfunction-associated fatty liver disease, and cardiovascular disease.

Key Points: 
  • The IDE approval launches the groundbreaking Remain-1 study, set to begin in the second half of 2024.
  • Remain-1 is a randomized, double-blind trial of Revita versus sham in patients who have lost at least 15% total body weight on tirzepatide therapy.
  • It is designed to be a pivotal study to potentially enable registrational filing for Revita for weight maintenance after GLP-1RA discontinuation.
  • The rationale for the Remain-1 pivotal study is based on a new need for therapeutic solutions that can offer durable weight maintenance without ongoing medical therapy.

Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors

Retrieved on: 
Thursday, March 28, 2024
Internal medicine, Boston Children's Hospital, Harvard Medical School, Swedish Orphan Biovitrum, Massachusetts General Hospital, Genzyme, Patient, SAN, Inflammation, Senior, Pediatrics, KIT, Hospital, Medicine, Management

SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors.

Key Points: 
  • SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors.
  • Prior to this role, he served as the President and Chief Executive Officer of Swedish Orphan Biovitrum AB (Sobi) from 2011 to 2017.
  • at Harvard Medical School and completed residency training in internal medicine and pediatrics at Massachusetts General Hospital and Boston Children's Hospital.
  • “I am excited to join the exceptional team at Third Harmonic Bio in working to expand the treatment landscape for mast cell disorders.”